NCT04928222View on ClinicalTrials.gov

Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 24, 2021

Primary Completion Date

December 30, 2023

Study Completion Date

June 30, 2024

Conditions
Basal Cell Carcinoma
Interventions
COMBINATION_PRODUCT

Doxorubicin-containing MNA

A 15 x 15 millimeter array containing 400 dissolvable microneedles delivering active agent

DRUG

Placebo-containing MNA

A 15 15 x 15 millimeter array containing 400 dissolvable microneedles containing placebo

Trial Locations (2)

10032

New York and Presbyterian Hospital, New York

33411

Beer Dermatology, West Palm Beach

All Listed Sponsors
lead

SkinJect, Inc.

INDUSTRY